Welcome to our dedicated page for Axsome Therapeut news (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeut stock.
Axsome Therapeutics (AXSM) is a clinical-stage biopharmaceutical leader developing innovative therapies for central nervous system disorders. This news hub provides investors and healthcare professionals with timely updates on clinical trial progress, regulatory milestones, and research breakthroughs.
Access comprehensive coverage of AXSM's developments including FDA submissions, partnership announcements, and scientific presentations. Our curated news collection features essential updates on depression treatments, narcolepsy therapies, and Alzheimer's-related research programs.
Key information categories include:
• Clinical trial results and phase updates
• Regulatory filings and approvals
• Research collaborations and licensing agreements
• Financial performance and strategic initiatives
Bookmark this page for direct access to verified Axsome Therapeutics announcements and expert analyses. Stay informed about pipeline developments in neurological treatment innovation through our continuously updated news repository.
Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, will release its Q2 2025 financial results on Monday, August 4, 2025, before U.S. markets open.
The company will host a conference call at 8:00 AM ET to discuss the results and provide business updates. Investors can join via phone or watch the webcast on Axsome's website, where a replay will be available for approximately 30 days.
Axsome Therapeutics (NASDAQ:AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, will host its Frontiers in Brain Health R&D Day on July 21, 2025 at 11:00 a.m. ET in New York City.
The event will showcase Axsome's late-stage CNS pipeline, featuring presentations from physician key opinion leaders discussing current neurology and psychiatry indications. The company's management team will provide detailed insights into their clinical development programs, followed by a Q&A session.
The R&D Day is specifically designed for institutional investors and sell-side analysts, with limited in-person attendance available through RSVP. A live webcast will be accessible to the public through the company's website.
Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company focused on CNS disorders, has announced its participation in three major investor conferences in June 2025:
- William Blair 45th Annual Growth Stock Conference - June 3, 2025, at 10:40 a.m. CT in Chicago
- Jefferies Global Healthcare Conference - June 5, 2025, at 2:35 p.m. ET in New York
- Goldman Sachs 46th Annual Global Healthcare Conference - June 9, 2025, at 2:40 p.m. ET in Miami Beach
Live webcasts will be available on Axsome's website, with replays accessible for approximately 30 days after each event.